Systematic evaluation of liver disease in hepatitis C virus-infected renal transplant recipients: clinical and pathological study

Berthoux, F; Berthoux, P; Mosnier, Jean‐François; Deeb, Salem El; Cecillon, S; Haem, J.

doi:10.1093/ndt/15.suppl_8.55

Cited by 5 publications

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ten‐year survival after transplantation is lower in this group of patients. About 80% of HCV− patients and 65% of HCV+ patients are alive in that period 43,83–85 . It is thought that immunosuppressive drugs (e.g., azathioprine) and hepatotropic viruses (e.g., HBV, CMV, and HIV) may intensify hepatocellular damage 25,86 .…”

Section: Hcv Infection In Kidney Transplant Recipientsmentioning

confidence: 99%

“…The most serious complication is acute parenchymatous or vascular transplant rejection or transplant necrosis 111 . Thus, INF therapy is not recommended in this patient group, except for those with chronic aggressive hepatitis 83,112,113 . Presently, a single study in the literature has reported on the positive treatment outcome of pegylated–INF‐α 2b in combination with ribavirin in HCV+ kidney transplant recipients.…”

Section: Hcv Infection Treatment In Dialysis Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Hepatitis C virus infection in dialysis patients

Sułowicz

Radziszewski

Chowaniec

2007

Hemodialysis International

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is a global health problem, common worldwide, leading to acute and chronic hepatitis and its consequences of hepatocirrhosis and hepatocellular carcinoma. Patients on hemodialysis belong to the high-risk group of HCV infection. The prevalence of HCV infection in dialysis patients ranges from 4% to more than 70% in some countries. The main reasons for such a high incidence of infections are a high prevalence of HCV infection in the general population, lack of standard infection precautions and effective vaccination, inadequate disinfection procedures of dialysis machines and other medical equipment, as well as spread of infection from patient to patient, especially in dialytic centers with a high percentage of infected patients. The diagnostic procedures useful in the evaluation of HCV infection are detection of anti-HCV antibodies, identification of HCV RNA, counts of virus copies, and identification of its genome. From the 6 major genotypes and multiple subtypes of the HCV, genotypes 1a and 1b are the most common in Europe and Japan, and 1b is responsible for more severe liver disease and aggressive course leading to liver fibrosis. Antiviral therapy of HCV+ dialysis patients with interferon-alpha (INF-alpha) gives slightly better results than in the general population, but is poorly tolerated and associated with side effects. Although ribavirin in not recommended for dialysis patients, the addition of small doses of this compound to pegylated INF is discussed, especially for patients in whom previous infection treatment failed.

show abstract

Section: Hcv Infection In Kidney Transplant Recipientsmentioning

confidence: 99%

Section: Hcv Infection Treatment In Dialysis Patientsmentioning

confidence: 99%